Gene Editing

Bill Gates Gets Excited About Future Of Tech That Has 'Revolutionized Health' Over Past Decade

Bill Gates Gets Excited About Future Of Tech That Has 'Revolutionized Health' Over Past Decade

Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection

Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection

FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials

FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials

Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection

Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection

FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials

FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials

Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents

Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents

Intellia Shares Updated Data On Gene Editing Durability In Rare Disease

Intellia Shares Updated Data On Gene Editing Durability In Rare Disease

Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents

Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents

Intellia Shares Updated Data On Gene Editing Durability In Rare Disease

Intellia Shares Updated Data On Gene Editing Durability In Rare Disease

Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership

Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership

Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs

Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs

Gene Editing Recent News

Jennifer Doudna Spinout Mammoth Inks $700M CRISPR Deal With Vertex

Jennifer Doudna Spinout Mammoth Inks $700M CRISPR Deal With Vertex

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology

Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients

Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients

Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate

Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate

Wave Life Sciences Shows Durable ADAR-Editing In Multiple Tissues In Animal Studies

Wave Life Sciences Shows Durable ADAR-Editing In Multiple Tissues In Animal Studies

Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection

Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection

Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies

Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies

Shape Therapeutics, Roche Form $3B RNA Editing Collaboration

Shape Therapeutics, Roche Form $3B RNA Editing Collaboration

Vertex Inks Potential $1.2B Gene-Editing Pact With Arbor Biotechnologies

Vertex Inks Potential $1.2B Gene-Editing Pact With Arbor Biotechnologies

Editas Medicine Unveils Preclinical Data From New Gene Editing Technology

Editas Medicine Unveils Preclinical Data From New Gene Editing Technology

Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish

Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish

A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc.

Heart Disease Company Tenaya Therapeutics Files For $100M US IPO

Heart Disease Company Tenaya Therapeutics Files For $100M US IPO

WHO Issues Framework For Governance For Gene Editing Technologies

WHO Issues Framework For Governance For Gene Editing Technologies

Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders

Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders

In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC

In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC

Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body.

Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate

Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate

Qiagen Launches CRISPR-Specific Products For Gene-Editing Experiments

Qiagen Launches CRISPR-Specific Products For Gene-Editing Experiments

Precision BioSciences Shares Move Higher As ARCUS Platform Shows Promising Gene Editing Approach For Transthyretin Amyloidosis

Precision BioSciences Shares Move Higher As ARCUS Platform Shows Promising Gene Editing Approach For Transthyretin Amyloidosis

Precision Bio's ARCUS Gene Editing Platform Is Safe, Durable; Long-Term Animal Study Shows

Precision Bio's ARCUS Gene Editing Platform Is Safe, Durable; Long-Term Animal Study Shows

Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications

Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications

Chinese 'Gene-Editing' Scientist Gets 3 Years In Prison

Chinese 'Gene-Editing' Scientist Gets 3 Years In Prison

Crispr's Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study

Crispr's Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study

Baird: Preclinical Data Inspires 'Early Optimism' In Lead Intellia Therapeutics Asset

Baird: Preclinical Data Inspires 'Early Optimism' In Lead Intellia Therapeutics Asset